Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia
Open Access
- 14 February 2014
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 4 (2) , e181
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBlood, 2013
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaBlood, 2012
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood, 2011
- Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An UpdateJournal of Clinical Oncology, 2011
- Instructive Role of the Transcription Factor E2A in Early B Lymphopoiesis and Germinal Center B Cell DevelopmentImmunity, 2008
- Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma SurvivalCancer Research, 2007
- Molecular cytogenetic characterization of TCF3 (E2A)/19p13.3 rearrangements in B‐cell precursor acute lymphoblastic leukemiaGenes, Chromosomes and Cancer, 2007
- The role of E2A-PBX1 in leukemogenesisOncogene, 2001
- λ5, a new light-chain-related locus selectively expressed in pre-B lymphocytesNature, 1986
- New chromosomal translocations correlate with specific immunophenotypes of childhood acute lymphoblastic leukemiaCell, 1984